A Phase 4 interventional study of bimatoprost ophthalmic solution 0.03% and bimatoprost vehicle solution in Hypotrichosis, sponsored by Allergan. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-05-22.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Hypotrichosis by AbbVie — none open to participants now, none under way, none of them phase 3. Hypotrichosis · AbbVie.
Among the 11 studies in Hypotrichosis by AbbVie, this one is one of 3 that started in 2011, is one of 3 in phase 4, and was the 7th registered.
24 studies on the registry are indexed under Hypotrichosis; 2 are open to participants now.
Browse Hypotrichosis studies →None of the 11 studies in Hypotrichosis by AbbVie is open now. The open studies under Hypotrichosis, anywhere →
Of the 2 Hypotrichosis studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2011.
This study's enrollment of 88 is above the median of 56 across 22 interventional studies indexed under Hypotrichosis.
Median enrollment 104 across the 9 interventional studies, 1,142 across the 2 observational. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Hypotrichosis by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
Drug: bimatoprost ophthalmic solution 0.03%
One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
Drug: bimatoprost vehicle solution
One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
Also known as: LATISSE®
One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall
Participants rated their overall eyelash satisfaction by answering Eyelash Satisfaction Questionnaire (ESQ-9) question #3: "Overall, how satisfied are you with your eyelashes?" using a 5-point scale: -2=very unsatisfied (worst), -1=unsatisfied, 0=neutral, 1=satisfied or 2=very satisfied (best). The percentage of participants who rated their satisfaction as 1=satisfied or 2=very satisfied at Week 16 is reported.
Time frame: Week 16
Percentage of Participants With at Least a 1-Grade Increase in the Global Eyelash Assessment (GEA) Score
The investigator evaluated the patient's overall eyelash prominence using the 4-point GEA scale: 1=minimal (worst), 2=moderate, 3=marked or 4=very marked (best). An at least a 1-grade increase in GEA score indicated improvement.
Time frame: Baseline, Week 16
| Milestone | Bimatoprost Ophthalmic Solution 0.03% | Bimatoprost Vehicle Solution |
|---|---|---|
| Started | 44 | 44 |
| Completed | 43 | 42 |
| Not completed | 1 | 2 |
Participants rated their overall eyelash satisfaction by answering Eyelash Satisfaction Questionnaire (ESQ-9) question #3: "Overall, how satisfied are you with your eyelashes?" using a 5-point scale: -2=very unsatisfied (worst), -1=unsatisfied, 0=neutral, 1=satisfied or 2=very satisfied (best). The percentage of participants who rated their satisfaction as 1=satisfied or 2=very satisfied at Week 16 is reported.
| Percentage of participants | Bimatoprost Ophthalmic Solution 0.03% | Bimatoprost Vehicle Solution |
|---|---|---|
| Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall | 67.4 | 7.1 |
The investigator evaluated the patient's overall eyelash prominence using the 4-point GEA scale: 1=minimal (worst), 2=moderate, 3=marked or 4=very marked (best). An at least a 1-grade increase in GEA score indicated improvement.
| Percentage of participants | Bimatoprost Ophthalmic Solution 0.03% | Bimatoprost Vehicle Solution |
|---|---|---|
| Percentage of Participants With at Least a 1-Grade Increase in the Global Eyelash Assessment (GEA) Score | 72.1 ± 0.37 | 19.0 ± 0.43 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bimatoprost Ophthalmic Solution 0.03% | — | 0/44 (0%) | 1/44 (2.3%) |
| Bimatoprost Vehicle Solution | — | 0/44 (0%) | 3/44 (6.8%) |
| Event | Bimatoprost Ophthalmic Solution 0.03% | Bimatoprost Vehicle Solution |
|---|---|---|
| NasopharyngitisInfections and infestations | 1/44 | 3/44 |
| Age Continuous(Years) | Bimatoprost Ophthalmic Solution 0.03% | Bimatoprost Vehicle Solution | Total |
|---|---|---|---|
| Mean | 49.2 ± 12.6 | 50.2 ± 10.5 | 49.7 ± 11.5 |
| Sex: Female, Male(Participants) | Bimatoprost Ophthalmic Solution 0.03% | Bimatoprost Vehicle Solution | Total |
|---|---|---|---|
| Female | 44 | 44 | 88 |
| Male | 0 | 0 | 0 |
The record gives a start of Oct 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimatoprost Ophthalmic Solution